Stockscreener 앱 받기
38.05
0.50%
-0.19
시간 외 거래:
37.87
-0.18
-0.47%
전일 마감가:
$38.24
열려 있는:
$38.24
하루 거래량:
1.40M
Relative Volume:
1.11
시가총액:
$6.99B
수익:
$520.18M
순이익/손실:
$-348.13M
주가수익비율:
-19.82
EPS:
-1.92
순현금흐름:
$-176.18M
1주 성능:
+11.32%
1개월 성능:
+4.56%
6개월 성능:
-24.37%
1년 성능:
-44.05%
1일 변동 폭
$36.77
$38.77
1주일 범위
$33.81
$38.77
52주 변동 폭
$30.17
$69.17
Legend Biotech Corp Adr Stock (LEGN) Company Profile
LEGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LEGN
Legend Biotech Corp Adr
|
38.05 | 6.99B | 520.18M | -348.13M | -176.18M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-08 | 개시 | Redburn Atlantic | Buy |
| 2024-06-17 | 개시 | Truist | Buy |
| 2024-05-24 | 재확인 | H.C. Wainwright | Buy |
| 2024-05-23 | 개시 | Deutsche Bank | Buy |
| 2024-04-17 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2024-04-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 개시 | Raymond James | Outperform |
| 2023-12-19 | 개시 | Scotiabank | Sector Perform |
| 2023-11-06 | 개시 | Goldman | Buy |
| 2023-05-25 | 개시 | William Blair | Mkt Perform |
| 2023-05-22 | 개시 | Daiwa Securities | Buy |
| 2023-03-29 | 개시 | H.C. Wainwright | Buy |
| 2023-03-24 | 개시 | RBC Capital Mkts | Outperform |
| 2022-12-06 | 개시 | UBS | Buy |
| 2022-11-02 | 개시 | Evercore ISI | Outperform |
| 2022-11-01 | 개시 | Cowen | Outperform |
| 2022-10-31 | 개시 | Guggenheim | Neutral |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-03-15 | 개시 | Barclays | Overweight |
| 2022-01-31 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-21 | 개시 | Piper Sandler | Overweight |
| 2021-05-18 | 개시 | BTIG Research | Buy |
| 2020-07-01 | 개시 | JP Morgan | Overweight |
| 2020-07-01 | 개시 | Jefferies | Buy |
| 2020-06-30 | 개시 | Morgan Stanley | Overweight |
모두보기
Legend Biotech Corp Adr 주식(LEGN)의 최신 뉴스
RBC Capital maintains Outperform rating on Legend Biotech shares - Investing.com
RBC Capital maintains Outperform rating on Legend Biotech shares By Investing.com - Investing.com South Africa
BMO Capital maintains Legend Biotech at Outperform with $90 target - Investing.com India
Piper Sandler maintains Overweight on Legend Biotech, $78 target - Investing.com India
Legend Biotech stock price target raised to $75 at H.C. Wainwright - Investing.com India
Legend Biotech reports Q4 earnings beat, revenue tops estimates By Investing.com - Investing.com South Africa
Legend Biotech reports Q4 earnings beat, revenue tops estimates - Investing.com India
Earnings call transcript: Legend Biotech Q4 2024 sees strong CARVICTI growth By Investing.com - Investing.com South Africa
Earnings call transcript: Legend Biotech Q4 2024 sees strong CARVICTI growth - Investing.com India
Compared to Estimates, Legend Biotech (LEGN) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
Legend Biotech CorpADR to Host Earnings Call - ACCESS Newswire
Arcutis Biotherapeutics (ARQT) Surges 15.9%: Is This an Indication of Further Gains? - Yahoo Finance
Market Momentum: Aptargroup Inc (ATR) Registers a 0.07 Increase, Closing at 143.28 - The Dwinnex
Legend Biotech Corp ADR (LEGN) rating initates by Redburn Atlantic - Knox Daily
A Guide To The Risks Of Investing In Worksport Ltd (WKSP) - Knox Daily
Legend Biotech Corp ADR (LEGN) stock analysis: A comprehensive overview - US Post News
Beyond Meat Inc (BYND)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Deeper Dive: Understanding Legend Biotech Corp ADR (LEGN) Through its Various Ratios - The Dwinnex
Legend Biotech Corp ADR (LEGN) looking to reclaim success with recent performance - SETE News
CIMG Inc (IMG)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Ratio Analysis: Unpacking XPLR Infrastructure LP (XIFR)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Ratios in Focus: Analyzing Aurora Mobile Ltd ADR (JG)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Analyze Legend Biotech Corp ADR (NASDAQ: LEGN) Before Investing. - Stocks Register
Legend Biotech's SWOT analysis: carvykti's efficacy drives stock potential amid competition - Investing.com India
Strength Seen in Eton Pharmaceuticals (ETON): Can Its 10.8% Jump Turn into More Strength? - Yahoo Finance
Legend Biotech stock target cut to $91 by Jefferies - Investing.com South Africa
Legend Biotech keeps stock at Buy rating on strong position - Investing.com India
When will lagging health care stocks return to healthy growth? - The Globe and Mail
Legend Biotech's SWOT analysis: carvykti's strong sales fuel stock's potential - Investing.com India
Legend Biotech's SWOT analysis: carvykti's strong sales fuel stock's potential By Investing.com - Investing.com South Africa
With BIOSECURE in limbo, should BeiGene or Legend sell itself in 2025? Analysts weigh in - FiercePharma
Legend Biotech's SWOT analysis: carvykti sales boost stock amid competition - Investing.com India
Legend Biotech's SWOT analysis: carvykti's promise drives stock outlook By Investing.com - Investing.com South Africa
Legend Biotech's SWOT analysis: carvykti's promise drives stock outlook - Investing.com India
Overweight rating for Legend Biotech reflects confidence in long-term CARVYKTI revenue - Investing.com India
Legend Biotech stock hits 52-week low at $32.65 amid market challenges - Investing.com
Legend Biotech's SWOT analysis: carvykti's efficacy drives stock potential amid challenges - Investing.com India
Legend Biotech stock hits 52-week low at $36.9 amid market shifts By Investing.com - Investing.com South Africa
Legend Biotech stock hits 52-week low at $36.9 amid market shifts - Investing.com
Analysts Expect ACWI To Hit $136 - Nasdaq
Earnings call: Legend Biotech sees strong growth with CARVICTI sales - Investing.com India
Earnings call: Legend Biotech sees robust growth with CARVICTI sales - Investing.com
Legend Biotech Corp ADR (NASDAQ: LEGN) Has Great Upside Potential - Stocks Register
Thinking Of Investing In Bilibili Inc ADR (NASDAQ: BILI) Stock? Read This First - Stocks Register
Are Medtronic Plc (NYSE: MDT) Analysts Predicting A Spike? - Stocks Register
Why Is Legend Biotech Corporation (LEGN) Among the Worst Performing Biotech Stocks in 2024? - Yahoo Finance
Parkway Corporate Limited Announces New Securities Issuance - MSN
Legend Biotech Corp Adr (LEGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.39%
0.55%
자본화:
|
볼륨(24시간):